Japan Large Molecule Drug Substance CDMO Market Insights Forecasts to 2033

• The Japan Large Molecule Drug Substance CDMO Market Size was valued at USD 307.5 Million in 2023.
• The Market Size is Growing at a CAGR of 11.09% from 2023 to 2033
• The Japan Large Molecule Drug Substance CDMO Market Size is Expected to Reach USD 880.5 Million by 2033

The Japan Large Molecule Drug Substance CDMO Market is anticipated to exceed USD 880.5 Million by 2033, growing at a CAGR of 11.09% from 2023 to 2033. The growing demand for biopharmaceuticals & large molecule therapies, biotechnological advancements, regulatory support and infrastructure improvement for biopharmaceutical manufacturing and outsourcing, and demand for specialized manufacturing capabilities and technical expertise by pharmaceutical companies are driving the growth of the large molecule drug substance CDMO market in the Japan.     

Market Overview

Large molecule drug substance CDMO is a contract development manufacturing organization that handles the outsourced manufacturing of large molecule drug substances and also all of the innovation and development work that occurs prior to manufacturing one. They are contracted by pharmaceutical companies to manufacture drug substances. Large molecules drug substances are fragile and complicated for formulation development. There is a need for designing large molecular medicinal material that is safe and effective while controlling time and expenses for development. Pharmaceutical companies, both local and foreign, depend on CDMOs. They effectively scale up production while retaining flexibility to adapt to changing market demands. In Japan large molecule drug substance CDMO market, Kanto is home to a large number of academic institutions, pharmaceutical businesses, and research facilities that are well-known for their contributions to drug discovery and biotechnology. Kanto’s strategic location appeals to CDMOs looking to set up operations with effective supply chain management and distribution skills because of this logistical advantage.

Report Coverage

This research report categorizes the market for the Japan large molecule drug substance CDMO market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan large molecule drug substance CDMO market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan large molecule drug substance CDMO market.

Driving Factors

The growing outsourcing of biopharmaceutical companies for the development of large molecule drug substances owing to the rising incidence of diseases in Japan is driving market growth. Kanto's significance in biopharmaceutical research and development is driving the market demand. Advancement in biotechnology and innovations such as cell culture techniques, genetic engineering, and high-throughput screening methods have up surged the capabilities of CDMOs for efficient and scalable production of complex biologics. Further, the collaborations and strategic partnerships are contributing to market growth. The rising emphasis on personalized medicine is leveraging market growth for the large molecule drug substance CDMO.

Restraining Factors

The complexities involved in technology transfer possess market challenges. Further, the supply chain vulnerabilities and raw material sourcing may also restrain market growth.  

Market Segmentation

The Japan Large Molecule Drug Substance CDMO Market share is classified into service, source, and end user.

• The contract manufacturing segment dominated the Japan large molecule drug substance CDMO market during the forecast period.  

The Japan large molecule drug substance CDMO market is segmented by service into contract manufacturing and contract development. Among these, the contract manufacturing segment dominated the Japan large molecule drug substance CDMO market during the forecast period. Pharmaceutical companies can concentrate on their core strengths, like research, clinical development, and commercialization, by using CM to outsource manufacture to companies with specialised knowledge of producing large-molecule medicinal substances. The growing demand for biopharmaceutical manufacturing capacity is driving the market.

• The mammalian segment is anticipated to grow at the fastest CAGR through the forecast period.

Based on the source, the Japan large molecule drug substance CDMO market is divided into mammalian, microbial, and others. Among these, the mammalian segment is anticipated to grow at the fastest CAGR through the forecast period. The capacity of mammalian cell culture to generate post-translational modifications is necessary for protein functionality and efficacy. They are commonly used in therapeutic applications as mammalian cell culture methods can generate complex proteins and biologics that closely match human proteins.  

• The biotech companies segment dominates the Japan large molecule drug substance CDMO market during the forecast period.       

Based on the end user, the Japan large molecule drug substance CDMO market is divided into biotech companies, CRO, and others. Among these, the biotech companies segment dominates the Japan large molecule drug substance CDMO market during the forecast period. Biotechnological companies focus on large molecules, advancements in biotechnology have expanded the pipeline of large molecules of drugs requiring CDMO services. The growing incidences of diseases and investments in R&D are anticipated to drive the market demand in the biotech companies segment.  

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan large molecule drug substance CDMO market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Chiyoda Corporation
• Sumitomo Chemical Co., Ltd.
• Terumo Corporation
• Bushu Pharmaceuticals
• Otsuka Chemical Co., Ltd.
• Nipro Corporation
• PharmaBio Corporation
• Zonnebodo Pharmaceutical Co., Ltd.
• Asahi Kasei Pharma Corporation
• RAHTO Pharmaceutical Co., Ltd.
• FUJIFILM Diosynth Biotechnologies
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In December 2023, Cytovance Biologics announced a strategic collaboration with fellow CDMO Alcami Corporation to expand its large molecule biologic manufacturing and sterile fill finish offering.

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Japan Large Molecule Drug Substance CDMO Market based on the below-mentioned segments:

Japan Large Molecule Drug Substance CDMO Market, By Service

• Contract Manufacturing
• Contract Development

Japan Large Molecule Drug Substance CDMO Market, By Source

• Mammalian
• Microbial
• Others

Japan Large Molecule Drug Substance CDMO Market, By End User

• Biotech Companies
• CRO
• Others